Elite Pharmaceuticals, Inc. filed a Form 8-K on November 12, 2026, announcing a conference call scheduled for November 13, 2026, to discuss financial results for its second quarter of fiscal year 2027, ended September 30, 2026.

Key Highlights

  • Filing date: The current report was filed November 12, 2026, by Elite Pharmaceuticals, Inc., a Nevada-incorporated pharmaceutical company trading as OTCQB:ELTP.
  • Event date and time: The earnings conference call is scheduled for Friday, November 13, 2026, at 11:30 AM EDT.
  • Fiscal period covered: The call will address results for the second quarter of fiscal year 2027, ended September 30, 2026.
  • Conference number: The dial-in conference number listed in the filing is 98840.
  • Signed by: The report was signed by Nasrat Hakim, President and CEO of Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Announces Q2 FY2027 Results Conference Call

According to the filing, Elite Pharmaceuticals, Inc. (OTCQB:ELTP), a Nevada corporation headquartered at 165 Ludlow Avenue, Northvale, New Jersey 07647, issued a press release on November 10, 2026, announcing that the company would host a conference call to discuss its financial results for the second quarter of fiscal year 2027. The quarter covered by the call ended September 30, 2026. The press release is attached to the filing as Exhibit 99.1 and incorporated by reference.

The filing was made under Item 2.02 ("Results of Operations and Financial Condition") and Item 7.01 ("Regulation FD Disclosure") of Form 8-K. As disclosed in the filing, the information furnished "shall not be deemed to be 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934." The filing further states that this current report "will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD." The company's common stock carries a par value of $0.001 per share and is listed on the OTCQB marketplace under the trading symbol ELTP.

The report was signed on November 12, 2026, by Nasrat Hakim in his capacity as President and CEO of Elite Pharmaceuticals, Inc. The filing also includes Exhibit 104, described as a Cover Page Interactive Data File embedded within the Inline XBRL document, in accordance with standard Form 8-K exhibit requirements.

What Was Disclosed

Elite Pharmaceuticals, Inc. filed a Form 8-K on November 12, 2026, disclosing a scheduled earnings conference call for November 13, 2026, at 11:30 AM EDT, covering the company's second quarter of fiscal year 2027 results for the period ended September 30, 2026.